Trial site
Gunma Prefectural Cancer Center
Ota-Shi, Gunma 373-8550, JapanNot linked to an institution yet
- 9running trials
- 2closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 1/22 trials
- Phase 21 trial
- Status
- Active, not recruiting8 trials
- Completed1 trial
- Recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer3 trials
- Amgen1 trial
- Daiichi Sankyo1 trial
- Genmab1 trial
- Innovent Biologics (Suzhou) Co. Ltd.1 trial
- and 4 more
Running trials
Recruiting
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Active, not recruiting
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562· Phase 1/2· Tanabe Pharma Corporation· Source
Active, not recruiting
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147· Phase 3· Jazz Pharmaceuticals· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error